New York-Precede Biosciences emerged from stealth mode on Thursday,advancing a blood based platform that can detect the presence of cancer and other diseases,and track dynamic changes in disease status in the context of treatment and other biological factors.
Since its establishment,Precede has received$57 million in funding support,and the company has developed a genome-wide method that uses 1 milliliter of plasma samples to analyze circulating chromatin to measure methylation and gene promotion.
Through technology currently only used for research,the company aims to provide services to the biopharmaceutical industry by identifying new targets associated with the biological mechanisms of diseases,as well as measuring biological signals of response and resistance to treatment.Meanwhile,Precede is developing blood based clinical tests internally to detect cancer and guide treatment decisions in oncology.
The company was established under the 4:59 program of 5AM Ventures and received support from 5AM Ventures and Binney Street Capital of Dana Farber Cancer Research Institute in the seed round,where the company's technology was originally conceived.The company's A-round financing was jointly led by 5AM Ventures and Lilly Asia Ventures,with Illumina Ventures,Bristol Myers Squibb,Osage University Partners,and the Qatar Investment Authority participating in the financing.
Precede stated that as part of its existing partnership,they have generated over 7000 genome-wide disease transcripts covering various cancers and other diseases.Researchers plan to present their first publicly available data for the first time at the 2023 European Society for Medical Oncology conference later this month.
Rehan Verjee,CEO and co founder of Precede,stated in a statement:"Our platform is a true pioneer in this field as it enables comprehensive analysis of disease site biology at the gene and pathway levels from a simple blood sample
The copyright of this article belongs to the original author and does not represent the position of our website.We have reproduced this article for the purpose of disseminating more information.If there are any copyright issues,please contact us for deletion.
